Collegium Pharmaceutical, Inc.
COLL
$27.92
$0.873.22%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 181.95M | 159.30M | 145.28M | 144.92M | 149.75M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 181.95M | 159.30M | 145.28M | 144.92M | 149.75M |
| Cost of Revenue | 24.22M | 20.41M | 19.96M | 18.95M | 20.60M |
| Gross Profit | 157.73M | 138.90M | 125.32M | 125.97M | 129.14M |
| SG&A Expenses | 58.65M | 42.07M | 43.34M | 41.98M | 32.94M |
| Depreciation & Amortization | 55.47M | 40.80M | 34.52M | 34.52M | 34.51M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 138.34M | 103.28M | 97.81M | 95.45M | 88.06M |
| Operating Income | 43.61M | 56.03M | 47.47M | 49.47M | 61.69M |
| Income Before Tax | 17.27M | 15.58M | 29.10M | 36.62M | 46.71M |
| Income Tax Expenses | 4.73M | 6.25M | 9.49M | 8.91M | 14.77M |
| Earnings from Continuing Operations | 12.54M | 9.34M | 19.61M | 27.71M | 31.94M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.54M | 9.34M | 19.61M | 27.71M | 31.94M |
| EBIT | 43.61M | 56.03M | 47.47M | 49.47M | 61.69M |
| EBITDA | 100.12M | 97.77M | 82.94M | 84.91M | 97.15M |
| EPS Basic | 0.39 | 0.29 | 0.60 | 0.86 | 0.99 |
| Normalized Basic EPS | 0.44 | 0.79 | 0.70 | 0.71 | 0.90 |
| EPS Diluted | 0.35 | 0.27 | 0.52 | 0.71 | 0.92 |
| Normalized Diluted EPS | 0.35 | 0.64 | 0.56 | 0.55 | 0.71 |
| Average Basic Shares Outstanding | 32.08M | 32.26M | 32.43M | 32.33M | 32.30M |
| Average Diluted Shares Outstanding | 40.11M | 40.16M | 40.38M | 41.44M | 41.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |